This document describes various in vivo and in vitro models used for screening potential antiparkinsonian drugs. Some key in vivo models mentioned include: 1) antagonism of tremors induced by tremorine/oxotremorine in mice, 2) use of the MPTP model in monkeys to induce Parkinson's disease-like symptoms, and 3) antagonism of sedation induced by reserpine in mice. Important in vitro/ex vivo models include measuring dopamine-stimulated adenylyl cyclase activity and radioligand binding studies for dopamine receptors. The document provides details on the procedures, evaluations, and modifications of these various screening models.
In this slide contains diabetics, classification, symptoms, complication, invivo and invitro screening models of anti diabetics.
Presented by: GEETHANJALI ADAPALA (Department of pharmacology).
RIPER, anantapur
Introduction to Screening Models of Anti-Atherosclerosis
Atherosclerosis, Screening models, In vitro models, In vivo models
Presented by
SHAIK FIRDOUS BANU
Department of Pharmacology
This seminar is my attempt to discuss screening of anti-emetic drugs using different animal models. The materials used in the presentation is derived from different standard textbooks, internet and journals. Please feel free to suggest ways to improve it.
Pharmacological screening of Anti-psychotic agentsAbin Joy
Presentation contents are:
Introduction, Definition of psychosis, Classification of anti-psychotics, MOA of anti-psychotic agents and screening models.
Preclinical Screening for Neurodegenerative Disease (Parkinsonism)Drx Burade
This file includes the general introduction of Parkinson's, sign and symptoms of Parkinson's, treatment of Parkinson's and the main content that is the Preclinical Screening models for Neurodegenerative disease like Parkinson's
In this slide contains diabetics, classification, symptoms, complication, invivo and invitro screening models of anti diabetics.
Presented by: GEETHANJALI ADAPALA (Department of pharmacology).
RIPER, anantapur
Introduction to Screening Models of Anti-Atherosclerosis
Atherosclerosis, Screening models, In vitro models, In vivo models
Presented by
SHAIK FIRDOUS BANU
Department of Pharmacology
This seminar is my attempt to discuss screening of anti-emetic drugs using different animal models. The materials used in the presentation is derived from different standard textbooks, internet and journals. Please feel free to suggest ways to improve it.
Pharmacological screening of Anti-psychotic agentsAbin Joy
Presentation contents are:
Introduction, Definition of psychosis, Classification of anti-psychotics, MOA of anti-psychotic agents and screening models.
Preclinical Screening for Neurodegenerative Disease (Parkinsonism)Drx Burade
This file includes the general introduction of Parkinson's, sign and symptoms of Parkinson's, treatment of Parkinson's and the main content that is the Preclinical Screening models for Neurodegenerative disease like Parkinson's
IN-VIVO SCREENING METHODS FOR NEURODEGENERATIVE DISEASE.pptxGautamSosa
Neurodegenerative diseases are conditions where nerve cells in the brain and peripheral nervous system gradually degenerate and die, leading to cognitive decline, movement disorders, and sometimes death. Examples include Alzheimer's, Parkinson's, multiple sclerosis and Huntington's disease. Treatment focuses on symptom management, as there are currently no cures for these conditions. Efficacy evaluation of any drug for Alzheimer's, Parkinson's, and multiple sclerosis in in-vivo animal studies, first step is to learn the in-vivo screening model of particular disease.
SCREENING METHODS OF ANTIPARKINSON DRUGSMangeshTatar
Parkinson's disease is a neurodegenerative disorder, which leads to progressive deterioration of motor function due to loss of dopamine-producing brain cells.
In this topic we cover Screening methods of Parkinsonism, pharmacology.
HOT NEW PRODUCT! BIG SALES FAST SHIPPING NOW FROM CHINA!! EU KU DB BK substit...GL Anaacs
Contact us if you are interested:
Email / Skype : kefaya1771@gmail.com
Threema: PXHY5PDH
New BATCH Ku !!! MUCH IN DEMAND FAST SALE EVERY BATCH HAPPY GOOD EFFECT BIG BATCH !
Contact me on Threema or skype to start big business!!
Hot-sale products:
NEW HOT EUTYLONE WHITE CRYSTAL!!
5cl-adba precursor (semi finished )
5cl-adba raw materials
ADBB precursor (semi finished )
ADBB raw materials
APVP powder
5fadb/4f-adb
Jwh018 / Jwh210
Eutylone crystal
Protonitazene (hydrochloride) CAS: 119276-01-6
Flubrotizolam CAS: 57801-95-3
Metonitazene CAS: 14680-51-4
Payment terms: Western Union,MoneyGram,Bitcoin or USDT.
Deliver Time: Usually 7-15days
Shipping method: FedEx, TNT, DHL,UPS etc.Our deliveries are 100% safe, fast, reliable and discreet.
Samples will be sent for your evaluation!If you are interested in, please contact me, let's talk details.
We specializes in exporting high quality Research chemical, medical intermediate, Pharmaceutical chemicals and so on. Products are exported to USA, Canada, France, Korea, Japan,Russia, Southeast Asia and other countries.
Couples presenting to the infertility clinic- Do they really have infertility...Sujoy Dasgupta
Dr Sujoy Dasgupta presented the study on "Couples presenting to the infertility clinic- Do they really have infertility? – The unexplored stories of non-consummation" in the 13th Congress of the Asia Pacific Initiative on Reproduction (ASPIRE 2024) at Manila on 24 May, 2024.
Ozempic: Preoperative Management of Patients on GLP-1 Receptor Agonists Saeid Safari
Preoperative Management of Patients on GLP-1 Receptor Agonists like Ozempic and Semiglutide
ASA GUIDELINE
NYSORA Guideline
2 Case Reports of Gastric Ultrasound
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
Title: Sense of Smell
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the primary categories of smells and the concept of odor blindness.
Explain the structure and location of the olfactory membrane and mucosa, including the types and roles of cells involved in olfaction.
Describe the pathway and mechanisms of olfactory signal transmission from the olfactory receptors to the brain.
Illustrate the biochemical cascade triggered by odorant binding to olfactory receptors, including the role of G-proteins and second messengers in generating an action potential.
Identify different types of olfactory disorders such as anosmia, hyposmia, hyperosmia, and dysosmia, including their potential causes.
Key Topics:
Olfactory Genes:
3% of the human genome accounts for olfactory genes.
400 genes for odorant receptors.
Olfactory Membrane:
Located in the superior part of the nasal cavity.
Medially: Folds downward along the superior septum.
Laterally: Folds over the superior turbinate and upper surface of the middle turbinate.
Total surface area: 5-10 square centimeters.
Olfactory Mucosa:
Olfactory Cells: Bipolar nerve cells derived from the CNS (100 million), with 4-25 olfactory cilia per cell.
Sustentacular Cells: Produce mucus and maintain ionic and molecular environment.
Basal Cells: Replace worn-out olfactory cells with an average lifespan of 1-2 months.
Bowman’s Gland: Secretes mucus.
Stimulation of Olfactory Cells:
Odorant dissolves in mucus and attaches to receptors on olfactory cilia.
Involves a cascade effect through G-proteins and second messengers, leading to depolarization and action potential generation in the olfactory nerve.
Quality of a Good Odorant:
Small (3-20 Carbon atoms), volatile, water-soluble, and lipid-soluble.
Facilitated by odorant-binding proteins in mucus.
Membrane Potential and Action Potential:
Resting membrane potential: -55mV.
Action potential frequency in the olfactory nerve increases with odorant strength.
Adaptation Towards the Sense of Smell:
Rapid adaptation within the first second, with further slow adaptation.
Psychological adaptation greater than receptor adaptation, involving feedback inhibition from the central nervous system.
Primary Sensations of Smell:
Camphoraceous, Musky, Floral, Pepperminty, Ethereal, Pungent, Putrid.
Odor Detection Threshold:
Examples: Hydrogen sulfide (0.0005 ppm), Methyl-mercaptan (0.002 ppm).
Some toxic substances are odorless at lethal concentrations.
Characteristics of Smell:
Odor blindness for single substances due to lack of appropriate receptor protein.
Behavioral and emotional influences of smell.
Transmission of Olfactory Signals:
From olfactory cells to glomeruli in the olfactory bulb, involving lateral inhibition.
Primitive, less old, and new olfactory systems with different path
- Video recording of this lecture in English language: https://youtu.be/lK81BzxMqdo
- Video recording of this lecture in Arabic language: https://youtu.be/Ve4P0COk9OI
- Link to download the book free: https://nephrotube.blogspot.com/p/nephrotube-nephrology-books.html
- Link to NephroTube website: www.NephroTube.com
- Link to NephroTube social media accounts: https://nephrotube.blogspot.com/p/join-nephrotube-on-social-media.html
Tom Selleck Health: A Comprehensive Look at the Iconic Actor’s Wellness Journeygreendigital
Tom Selleck, an enduring figure in Hollywood. has captivated audiences for decades with his rugged charm, iconic moustache. and memorable roles in television and film. From his breakout role as Thomas Magnum in Magnum P.I. to his current portrayal of Frank Reagan in Blue Bloods. Selleck's career has spanned over 50 years. But beyond his professional achievements. fans have often been curious about Tom Selleck Health. especially as he has aged in the public eye.
Follow us on: Pinterest
Introduction
Many have been interested in Tom Selleck health. not only because of his enduring presence on screen but also because of the challenges. and lifestyle choices he has faced and made over the years. This article delves into the various aspects of Tom Selleck health. exploring his fitness regimen, diet, mental health. and the challenges he has encountered as he ages. We'll look at how he maintains his well-being. the health issues he has faced, and his approach to ageing .
Early Life and Career
Childhood and Athletic Beginnings
Tom Selleck was born on January 29, 1945, in Detroit, Michigan, and grew up in Sherman Oaks, California. From an early age, he was involved in sports, particularly basketball. which played a significant role in his physical development. His athletic pursuits continued into college. where he attended the University of Southern California (USC) on a basketball scholarship. This early involvement in sports laid a strong foundation for his physical health and disciplined lifestyle.
Transition to Acting
Selleck's transition from an athlete to an actor came with its physical demands. His first significant role in "Magnum P.I." required him to perform various stunts and maintain a fit appearance. This role, which he played from 1980 to 1988. necessitated a rigorous fitness routine to meet the show's demands. setting the stage for his long-term commitment to health and wellness.
Fitness Regimen
Workout Routine
Tom Selleck health and fitness regimen has evolved. adapting to his changing roles and age. During his "Magnum, P.I." days. Selleck's workouts were intense and focused on building and maintaining muscle mass. His routine included weightlifting, cardiovascular exercises. and specific training for the stunts he performed on the show.
Selleck adjusted his fitness routine as he aged to suit his body's needs. Today, his workouts focus on maintaining flexibility, strength, and cardiovascular health. He incorporates low-impact exercises such as swimming, walking, and light weightlifting. This balanced approach helps him stay fit without putting undue strain on his joints and muscles.
Importance of Flexibility and Mobility
In recent years, Selleck has emphasized the importance of flexibility and mobility in his fitness regimen. Understanding the natural decline in muscle mass and joint flexibility with age. he includes stretching and yoga in his routine. These practices help prevent injuries, improve posture, and maintain mobilit
Title: Sense of Taste
Presenter: Dr. Faiza, Assistant Professor of Physiology
Qualifications:
MBBS (Best Graduate, AIMC Lahore)
FCPS Physiology
ICMT, CHPE, DHPE (STMU)
MPH (GC University, Faisalabad)
MBA (Virtual University of Pakistan)
Learning Objectives:
Describe the structure and function of taste buds.
Describe the relationship between the taste threshold and taste index of common substances.
Explain the chemical basis and signal transduction of taste perception for each type of primary taste sensation.
Recognize different abnormalities of taste perception and their causes.
Key Topics:
Significance of Taste Sensation:
Differentiation between pleasant and harmful food
Influence on behavior
Selection of food based on metabolic needs
Receptors of Taste:
Taste buds on the tongue
Influence of sense of smell, texture of food, and pain stimulation (e.g., by pepper)
Primary and Secondary Taste Sensations:
Primary taste sensations: Sweet, Sour, Salty, Bitter, Umami
Chemical basis and signal transduction mechanisms for each taste
Taste Threshold and Index:
Taste threshold values for Sweet (sucrose), Salty (NaCl), Sour (HCl), and Bitter (Quinine)
Taste index relationship: Inversely proportional to taste threshold
Taste Blindness:
Inability to taste certain substances, particularly thiourea compounds
Example: Phenylthiocarbamide
Structure and Function of Taste Buds:
Composition: Epithelial cells, Sustentacular/Supporting cells, Taste cells, Basal cells
Features: Taste pores, Taste hairs/microvilli, and Taste nerve fibers
Location of Taste Buds:
Found in papillae of the tongue (Fungiform, Circumvallate, Foliate)
Also present on the palate, tonsillar pillars, epiglottis, and proximal esophagus
Mechanism of Taste Stimulation:
Interaction of taste substances with receptors on microvilli
Signal transduction pathways for Umami, Sweet, Bitter, Sour, and Salty tastes
Taste Sensitivity and Adaptation:
Decrease in sensitivity with age
Rapid adaptation of taste sensation
Role of Saliva in Taste:
Dissolution of tastants to reach receptors
Washing away the stimulus
Taste Preferences and Aversions:
Mechanisms behind taste preference and aversion
Influence of receptors and neural pathways
Impact of Sensory Nerve Damage:
Degeneration of taste buds if the sensory nerve fiber is cut
Abnormalities of Taste Detection:
Conditions: Ageusia, Hypogeusia, Dysgeusia (parageusia)
Causes: Nerve damage, neurological disorders, infections, poor oral hygiene, adverse drug effects, deficiencies, aging, tobacco use, altered neurotransmitter levels
Neurotransmitters and Taste Threshold:
Effects of serotonin (5-HT) and norepinephrine (NE) on taste sensitivity
Supertasters:
25% of the population with heightened sensitivity to taste, especially bitterness
Increased number of fungiform papillae
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
2. INTRODUCTION
It is a progressive neurodegenerative disorder .
Their is a marked deficiency in the dopaminergic
innervation of the basal ganglia owing to
degeneration of neurones in the substantia nigra.
Enhancement of dopaminergic transmission restores
at least partially motor function.
The decrease in dopaminergic activity in the basal
ganglia results in a relative excess of cholinergic
influence.
Therefore, dopaminergic agonists, such as levodopa, a
precursor of dopamine, and cholinergic (muscarinic)
antagonists can be combined in the treatment of
Parkinson’s disease.
3. SCREENING MODELS
I. IN VIVO MODELS
a)Tremorine and oxotremorine antagonism
b)MPTP model in monkeys
c)Reserpine antagonism
d)Circling behavior in nigrostriatal lesioned
rats
e)Elevated body swing test
f)Skilled paw reaching in rats
g)Stepping test in rats
4. II. IN VITRO AND EX VIVO MODELS
a. Experiments using rat striatal slices
b. Dopamine stimulated Adenylyl Cyclase
activity
c. Radioligand binding studies for D1 and D2
Dopamine receptors
d. Dopamine release from synaptosomes
5. a. Tremorine and oxotremorine antagonism
–
PURPOSE AND RATIONALE
The muscarinic agonists tremorine and oxotremorine
induce parkinsonism-like signs such as tremor, ataxia,
spasticity, salivation, lacrimation and hypothermia.
These signs are antagonized by anticholinergic drugs.
PROCEDURE
Groups of 6-10 male NMRI mice weighing 18–22 g
are used.
They are dosed orally with the test compound or the
standard (5 mg/kg benzatropine mesilate) 1 h prior
the administration of 0.5 mg/kg oxotremorine s.c.
6. Rectal temperature is measured before
administration of the compound (basal value) and
1, 2 and 3 h after oxotremorine injection.
Tremor is scored after oxotremorine dosage in 10 s
observation periods every 15 min for 1 h.
Tremor Score
absent 0
slight 1
medium 2
severe 3
7. Salivation and lacrimation are scored 15 and 30 min
after oxotremorine injection.
absent 0
slight 1
medium 2
severe 3
EVALUATION
Hypothermia
The differences of body temperature after 1, 2 and 3 h
versus basal values are summarized for each animal
in
the control group and the test groups.
The average values are compared statistically.
8. Tremor
The scores for all animals in each group at the 3
observation periods are summarized.
The numbers in the treated groups are expressed
as percentage of the number of the control group.
Salivation and lacrimation
The scores for both symptoms for all animals in
each
group are summarized at the 2 observation
periods.
The numbers in the treated groups are expressed
as percentage of the number of the control group.
9. MODIFICATIONS OF THE METHOD
Johnson et al. (1986)
Developed a procedure for quantifying whole-
body tremors in mice.
Displacement of a free floating platform by
animal movement created a change in resistance
across a strain gauge.
Administration of oxotremorine, 2.5 mg/kg, i.p,
produced numerous high-frequency, high-
intensity peaks within 5 min.
10. Clement and Dyck (1989)
Constructed and tested a tremor monitor that quantitates
soman- and oxotremorine-induced tremors.
The device consisted of a force transducer, from which a
plastic beaker was suspended containing a mouse.
The signal from the force transducer was fed into a tremor
monitor and quantitated using the Applecounter from
Columbus Instruments.
Coward et al. (1977)
Recommended N-carbamoyl-2-(2,6-
dichlorophenyl)acetamidine hydrochloride (LON-
1954), a tremorigenic agent, as alternative to
oxotremorine for the detection of anti-Parkinson
drugs
11. b. MPTP model in monkeys
PURPOSE AND RATIONALE
N-MPTP (N-methyl-4-phenyl-1,2,3,6-
tetrahydropyridine) has been shown to cause
symptoms of Parkinson’s disease in exposed
individuals.
When administered to primates this compound
causes a partial destruction of basal ganglia and a
syndrome that resembles Parkinson’s disease.
13. PROCEDURE
Burns et al. (1983) treated 8 adult rhesus monkeys
weighing 5–8 kg over a period of 5–8 days with
cumulative intravenous doses of N-methyl-4-phenyl-
1,2,3,6-tetrahydropyridine (N-MPTP) up to 10–18
mg/kg.
These animals showed a parkinsonism like disorder
(akinesia, rigidity, postural tremor, flexed posture,
eyelid closure, drooling)
Which was reversed by the administration of L-dopa.
The pathological and biochemical changes produced
by N-MPTP are similar to the well established
changes in patients with Parkinsonism.
14. EVALUATION
The severity of parkinsonian symptoms is rated by
trained observers
movement (0: normal; 1: reduced; 2: sleepy)
checking movements (0: present; 1: reduced; 2:
absent)
attention and blinking (0: normal; 1: abnormal)
posture (0: normal; 1: abnormal trunk; 2: abnormal
trunk and tail; 3: abnormal trunk, tail, and limbs; 4:
flexed posture)
balance and coordination (0: normal; 1: impaired; 2:
unstable; 4: falls)
reactions (0: normal; 1: reduced; 2: slow; 3: absent)
vocalizations (0: normal; 1: reduced; 2: absent).
15. MODIFICATIONS OF THE METHOD
Kebabian et al. (1992) tested a selective D1 receptor
agonist with antiparkinsonian activity in MTPT
treated marmosets.
Domino and Sheng (1993) studied the relative
potency of some dopamine agonists with varying
selectivities for D1 and D2 receptors in MPTP-induced
hemiparkinsonian monkeys.
Asin et al. (1997) tested a selective D1 receptor agonist
in rats previously given unilateral 6
hydroxydopamine injections and in macaques
previously given unilateral, intracarotid infusions of
MPTP.
16. c. Reserpine antagonism
PURPOSE AND RATIONALE
Reserpine induces depletion of central catecholamine
stores.
The sedative effect can be observed in mice shortly
after injection, followed by signs of eyelid ptosis,
hypokinesia, rigidity, catatonia, and immobility.
These phenomena can be antagonized by dopamine
aonists.
17. MODIFICATIONS OF THE METHOD
Rats treated with reserpine develop spontaneous
orofacial dyskinesia that has features similar to
tardive dyskinesia in humans (Nisewander et al.
1994).
The incidence of tongue protrusions was recorded to
quantify the occurrence of oral dyskinesia.
18. d. Circling behavior in nigrostriatal
lesioned rats
PURPOSE AND RATIONALE
Unilateral lesion of the dopaminergic nigrostriatal
pathway in the rat by the neurotoxin 6-
hydroxydopamine (6OHDA) induces hypersensitivity
of the postsynaptic dopaminergic receptors in the
striatum of the lesioned side.
The rats rotate in a direction towards the lesioned
side (ipsilateral) when an indirect acting compound
such
as amphetamine is administered but to the opposite
direction (contralateral) when a direct acting
dopamine agonist, e.g., apomorphine, or the
dopamine precursor L-dopa is given.
19. Therefore, this test can be used for the study of
central dopamine function and the evaluation of
dopamine antagonists and agonists, particularly the
activity of novel antiparkinsonian drugs.
MODIFICATIONS OF THE METHOD
Etemadzadeh et al. (1989) described a computerized
rotometer apparatus for recording circling behavior
Hudson et al. (1993) described a 16-channel
automated rotometer system for reliable
measurement of turning behavior in 6-
hydroxydopamine lesioned and transplanted rats
Garrett and Holtzman (1996) compared the effects of
apomorphine, cocaine and caffeine on locomotor
activity and rotational behavior in rats with unilateral
6-OHDA-induced lesions of the nigrostriatal tract.
20. e. Elevated body swing test
PURPOSE AND RATIONALE
Borlongan and Sanberg (1995) proposed the elevated
body swing test as a measure of asymmetrical motor
behavior of hemiparkinsonian animals in a drug-free
state.
f. Skilled paw reaching in rats
PURPOSE AND RATIONALE
Barnéoud et al. (1996) used the skilled paw reaching
test as a model of Parkinson’s disease in the rat.
21. Unilateral injection of 6-OHDA into the medial
forebrain bundle results in an impairment of paw
reaching on both sides which can be ameliorated by
drug treatment or transplantation of a nigral cell
suspension.
g. Stepping test in rats
PURPOSE AND RATIONALE
Schallert et al. (1992), Olsson et al. (1995) introduced
the stepping test as a clinically relevant unilateral
model of Parkinsonian akinesia.
The 6-OHDA lesion induced marked and long-lasting
impairments in the initiation of stepping movements
with the contralateral paw which can be ameliorated
by the systemic application of drugs.
22. II. IN VITRO AND EX VIVO MODELS
a.Dopamine- stimulated Adenylyl cyclase activity.
23. REFERANCES
Drug Discovery and Evalution by H.
Gerhard Vogel. II nd Ed.
Drugs Screening Methods By S. K.
Gupta.
www.google.com